The USPSTF evaluation (1) and supporting articles are plagued with ambiguity over the terms “screen” and “screening” when used alone and in conjunction with the term “mammography.” Whereas the evidence of benefit has been drawn exclusively from intention-to-treat publications, the numerical conclusions have been directly applied by the USPSTF to the individual woman seeking advice from her physician. If the USPSTF evaluation is taken at face value, women will be told the estimated benefit of receiving an invitation to participate in a mammography screening program. This estimated benefit is considerably lower, by a factor of approximately 1.4, than the actual benefit of mammography (4). On the contrary, the harms estimated by the USPSTF are not calculated on an intention-to-treat basis, which introduced bias into the risk–benefit calculations.